Rocha-de-Lossada, CarlosLinero, Carmen AlbaSantos-Ortega, AlvaroRodriguez-Calvo-de-Mora, MarinaRachwani, RahulBorroni, DavideAlba, EmilioBenavides-Orgaz, ManuelRomano, Vito2023-05-032023-05-032021-02-09Rocha-de-Lossada C, Linero CA, Ortega ÁS, Calvo-de-Mora MR, Rachwani R, Borroni D, et al. Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports. Arq Bras Oftalmol. 2021 Sep 10;85(4):411-414http://hdl.handle.net/10668/21667The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Glioblastoma/drug therapyAntibodies, monoclonal, humanized/therapeutic useCornea/drug effectsVisual disorders/etiologyCase reportsAntibodies, Monoclonal, HumanizedHumansImmunoconjugatesVision Disordersresearch article34586240open accessGlioblastomaToxicidadAgudeza visualQueratitisGotas lubricantes para ojos10.5935/0004-2749.202200391678-2925